Showing 1 - 3 results of 3 for search '"selective estrogen receptor modulator"', query time: 0.08s Refine Results
  1. 1

    Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. by Rizzoli, R, Reginster, J, Boonen, S, Bréart, G, Diez-Perez, A, Felsenberg, D, Kaufman, J, Kanis, J, Cooper, C

    Published 2011
    “…Cutaneous effects and osteonecrosis of the jaw are of concern for denosumab (both very rare), though there are no pharmacovigilance data for this agent yet. The selective estrogen receptor modulators are associated with hot flushes, leg cramps, and, very rarely, venous thromboembolism and stroke. …”
    Journal article
  2. 2

    Assessment of cardiovascular safety of anti-osteoporosis drugs by Fuggle, NR, Cooper, C, Harvey, NC, Al-Daghri, N, Brandi, M-L, Bruyere, O, Cano, A, Dennison, EM, Diez-Perez, A, Kaufman, J-M, Palacios, S, Prieto Alhambra, D, Rozenberg, S, Thomas, T, Tremollieres, F, Rizzoli, R, Kanis, JA, Reginster, JY

    Published 2020
    “…Despite findings in the early 21st century that menopausal hormone therapy was associated with coronary artery disease and venous thromboembolism (VTE), this therapy is now thought to be potentially safe (from a cardiac perspective) if started within the first 10 years of the menopause. Selective estrogen receptor modulators (SERMs) are associated with increased risk of VTE and may be related to fatal strokes (a subset of total strokes). …”
    Journal article
  3. 3

    Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the... by Cooper, C, Reginster, J, Cortet, B, Diaz-Curiel, M, Lorenc, R, Kanis, J, Rizzoli, R

    Published 2012
    “…METHODS: We reviewed the efficacy and safety of calcium and vitamin D, the selective estrogen receptor modulators (SERMs), the bisphosphonates, denosumab, and strontium ranelate in studies of 3 years or longer. …”
    Journal article